Control-IQ Technology Positively Impacts Patient Reported Outcome Measures and Glycemic Control in Youth with Type 1 Diabetes in a Real-World Setting

Table 2

Patient-reported outcome measures (PROM) at baseline and 16 weeks after initiation of Control-IQ technology.

PROM (total score)	Youth						Parents
	Pre		Post		Mean difference (post-baseline) (95% CI)	value^1	Pre		Post		Mean difference (postbaseline) (95% CI)	value^1
	N	Mean (SD) or median (IQR)	N	Mean (SD) or median (IQR)			N	Mean (SD) or median (IQR)	N	Mean (SD) or median (IQR)
INSPIRE (1–100)	49	76.8 (14.0)	49	73.0 (11.6)	−3.98 (−8.51, 0.54)	0.08	54	74.6 (9.2)	45	70.7 (12.2)	−3.49 (−6.88, −0.10)	0.04
DIDS
Diabetes Impact (0–10)	49	4.4 (1.9)	49	3.2 (1.4)	−1.08 (−1.51, −0.64)	<0.001	53	5.0 (1.7)	43	3.6 (1.4)	−1.41 (−1.96, −0.87)	<0.001
Device Satisfaction (0–10)	49	8.0 (1.2)	49	8.5 (1.0)	0.43 (0.11, 0.74)	0.01	53	7.9 (0.9)	43	8.4 (0.8)	0.58 (0.31, 0.85)	<0.001
HFS
Overall	49	40.3 (15.4)	49	36.2 (13.0)	−4.41 (−7.65, −1.17)	0.01	52	51.3 (16.2)	43	42.9 (15.4)	−7.64 (−11.66, −3.62)	<0.001
Behavior (0–40)	49	20.4 (6.5)	49	20.5 (5.3)	−0.46 (−1.95, 1.04)	0.54	52	23.9 (5.2)	43	20.5 (6.3)	−2.87 (−4.37, −1.38)	<0.001
Worry (0–60)	49	19.9 (13.1)	49	15.7 (10.6)	−3.96 (−6.51, −1.40)	0.003	52	27.4 (13.0)	43	22.4 (11.1)	−4.77 (−8.09, −1.45)	0.01
WHO-5 (0–100)	49	60.0 (48.0, 76.0)^2	49	72.0 (60.0, 80.0)^2	5.1 (−1.4, 11.6)	0.12	56	68.0 (55.0, 76.0)^2	43	76.0 (68.0, 80.0)^2	9.6 (3.4, 15.8)	0.003

¹t-test for paired samples to compare the difference in means. ²Median (interquartile range) is reported.